| Training cohort | Test cohort | ||
---|---|---|---|---|
CHB (n = 63) | HCC (n = 46) | CHB (n = 41) | HCC (n = 71) | |
Gender | ||||
Female | 21 (33.3%) | 6 (13.6%) | 18 (43.9%) | 13 (18.3%) |
Male | 42 (66.7%) | 38 (86.4%) | 22 (53.7%) | 58 (81.7%) |
Age | 36.6 ± 13.8 | 52.4 ± 8.3 | 40.1 ± 11.9 | 51.1 ± 10.2 |
Serum HBV DNA | 7.48 | 5.02 | 6.24 | 5.32 |
(log10 IU/ml) | (6.50–7.83) | (4.43–6.25) | (4.89–7.65) | (4.80–5.85) |
TBIL (μmol/L) | 13 | 14.2 | 11 | 14.5 |
 | (10.0–17.0) | (11.1–19.8) | (8.7–15.7) | (11.5–19.4) |
DBIL (μmol/L) | 3 | 5.5 | 4 | 5.7 |
 | (3.0–5.0) | (4.0–7.7) | (3.0–6.0) | (4.4–7.5) |
TP (g/L) | 74 | 68.8 | 75 | 67.8 |
 | (71.5–79.0) | (64.4–71.1) | (70.0–78.0) | (64.1–72.7) |
ALB (g/L) | 45.5 | 39.8 | 45 | 40.9 |
 | (41.0–49.7) | (37.0–42.5) | (43.0–48.5) | (38.0–43.9) |
ALT (U/L) | 38 | 43.4 | 51 | 40.5 |
 | (19.0–66.0) | (24.7–78.4) | (29.5–77.0) | (33.0–71.0) |
AST (U/L) | 30 | 46 | 33 | 40 |
 | (21.0–45.0) | (25.0–84.5) | (26.5–54.2) | (31.0–64.0) |
GGT (U/L) | 22 | 81 | 24 | 78 |
 | (15.0–51.0) | (41.3–156.0) | (18.0–43.2) | (50.0–121.5) |
ALP (U/L) | 71.5 | 92 | 72 | 92 |
 | (59.299.7) | (69.25–131.5) | (56.0–82.5) | (73.5–112.0) |
HBsAb | ||||
Negative | 17 (40.5%) | 36 (85.7%) | 38 (97.4%) | 64 (95.5%) |
Postive | 25 (59.5%) | 6 (14.3%) | 1 (2.6%) | 3 (4.5%) |
HBeAg | ||||
Negative | 31 (73.8%) | 25 (59.5%) | 8 (20.5%) | 41 (61.2%) |
Postive | 11 (26.2%) | 17 (40.5%) | 31 (79.5%) | 26 (38.8%) |
HBeAb | ||||
Negative | 33 (78.6%) | 10 (23.8%) | 31 (79.5%) | 18 (26.9%) |
Postive | 9 (21.4%) | 32 (76.2%) | 8 (20.5%) | 49 (73.1%) |
HBV genotype | ||||
B | 26(41.2%) | 8(17.4%) | 15(36.6%) | 12(16.9%) |
C | 37(58.7%) | 36(78.3%) | 26(63.4%) | 59(83.1%) |
Tumor size(cm) |  | 5.6(3.32–9.40) |  | 11(7.8–14.5) |
Capsule | Â | |||
Intact | Â | 5 (11.4%) | Â | 10 (15.6%) |
None | Â | 5 (11.4%) | Â | 11 (17.2%) |
Partial | Â | 34 (77.3%) | Â | 43 (67.2%) |
Tumor number | ||||
1 | Â | 32 (72.7%) | Â | 58 (90.6%) |
2 | Â | 0 (0.0%) | Â | 3 (4.7%) |
3 | Â | 12 (27.3%) | Â | 3 (4.7%) |
PVTT | ||||
None | Â | 23 (52.3%) | Â | 45(63.3%) |
Yes | Â | 21 (47.7%) | Â | 19 (29.7%) |
AFP(ng/ml) |  | 565 (29.1–15,375.0) |  | 187 (7.83–1210.0) |